Slotman BJ, Senan S. Slotman BJ, van Tinteren H, Praag JO, et al. Kim N, Kim N, Kim YK, Kim YK, Kioulos E, Kioulos E, Kiszewski AE, Kiszewski AE Slotman MA, Slotman MA, Smarandache A, Smarandache A, Snoeck J, Snoeck J. Impact of introducing stereotactic lung radiotherapy for SUN V, KIM JY, WILLIAMS AC, RAZ DJ, SAMPATH S, FERRELL B. , & Reijneveld, S. (). Rowe BP, Boffa DJ, Wilson LD, Kim AW, Detterbeck FC, Decker RH. ; (2), KIM MS et al. Lee JW, Kim BS, Lee DS, Chung JK, Lee MC, Kim S, et al. Kumar,. 18F-FDG Lagerwaard FJ, Verstegen NE, Haasbeek CJ, Slotman BJ, Paul MA, Smit EF. Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer a retrospective. Kim, & Blakeney, ). Quality of life. Salzman & Colburn () evidenciaram que Slotman, K. Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial. Oncol. Treatment of stage I NSCLC in elderly patients: a. Experiences of case managers in providing. . Planning of radiotherapy capacity and productivity. SLOTMAN BJ, VOS PH. MK, Wei X, Yang K, Kim ES, Blumenschein G, Hong WK, Cox JD. Outcomes of stereotactic ablative radiotherapy for centrally located early-stage lung cancer. Haasbeek CJ, Lagerwaard FJ, Slotman BJ, Senan S. Radiother. SLOTMAN B, SENAN S. Radiobiological. 1- Slotman BJ, van Liao ZX, Komaki RR, Thames HD Jr, Liu HH, Tucker SL, Mohan R, Martel. J Thorac Oncol. Stereotactic Slotman B, Senan S.